Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DXR vs PLSE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PLSE Captures Overall Composite Edge (40.1 SELL vs 52.2 HOLD), While DXR Leads 3–2 on Growth & Valuation Pillars

PLSE Overall Winner 6-Pillar Tally: DXR 3 – 2 PLSE (1 Tie) Matrix Metrics: DXR 6 – 4 PLSE

As of Nov 16, 2026, Pulse Biosciences, Inc (PLSE) captures the overall head-to-head institutional edge over Daxor Corporation (DXR) on higher Unified Composite conviction (40.1/100 SELL vs. 52.2/100 HOLD) after splitting the core matrix 4–6 (led by Growth & Scale, Options & Positioning), while DXR wins 3–2 across the 6-pillar growth and valuation breakdown. DXR trades at $8.36 (64.5x Forward P/E, -5894.3% operating margin) versus PLSE at $46.36 (N/M Forward P/E, -5861.2% operating margin).

  • Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. PLSE 40.1/100 SELL), PLSE captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-5861.2% vs. -5894.3% operating margin) and revenue trajectory (+359.3% vs. +25.5% YoY).
  • Technical & Structure Timing Caution: DXR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile PLSE trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 40.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DXR vs PLSE
DXR NASDAQ
Daxor Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$8.36
-1.47% 1D
Market Cap $49.5M
TTM Revenue $31,360
Forward P/E 64.5x
Beta / 30D Vol 0.28β · 32% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 52.0 Fund 59.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $8.91 · SMA50: $10.07
PLSE NASDAQ Head-to-Head Winner
Pulse Biosciences, Inc Common Stock (DE)
Surgical & Medical Instruments & Apparatus
$46.36
-8.09% 1D
Market Cap $3.7B
TTM Revenue $1.5M
Forward P/E N/M
Beta / 30D Vol 1.71β · 78% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 46.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 40.3 · SMA20: $53.15 · SMA50: $51.72

6-Pillar Scorecard Institutional Category Breakdown (DXR 3 – 2 PLSE)

Columns: Metric · DXR · PLSE
1. Valuation Multiples DXR
Forward P/E 64.5x N/M
Trailing P/E 7.7x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale PLSE
Revenue Growth (YoY) +25.5% +359.3%
Earnings Growth (YoY) +329.3% +0.0%
TTM Revenue (USD) $31,360 $1.5M
Market Cap $49.5M $3.7B
3. Profitability & Quality DXR
Gross Margin 100.0% 26.8%
Operating Margin -5894.3% -5861.2%
Net Profit Margin 19861.4% 0.0%
Return on Equity (ROE) 14.2% -60.6%
4. Balance Sheet & Cash Flow DXR
Cash Generation (TTM) N/A -$64M
Cash Flow Margin N/A N/A
Net Cash / Leverage $8.88 Book/Sh · 14.2% ROE $30M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PLSE
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 73.5% (10th %ile)
Put/Call OI Skew N/A 0.70x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DXR (6) vs PLSE (4)
Institutional Metric DXR PLSE Criterion Row Edge
Market Capitalization
Scale
$49.5M $3.7B Larger Scale PLSE
Trailing P/E Ratio
Valuation
7.7x N/M Lower Multiple DXR
Forward P/E Ratio
Valuation
64.5x N/M Lower Multiple DXR
Revenue Growth (YoY)
Growth
+25.5% +359.3% Higher Growth PLSE
Operating Margin (TTM)
Profitability
-5894.3% -5861.2% Higher Margin PLSE
Net Profit Margin
Profitability
19861.4% 0.0% Higher Margin DXR
Return on Equity (ROE)
Capital Efficiency
14.2% -60.6% Higher ROE DXR
52-Week Range Position
Momentum
2% ($8–$15) 73% ($13–$59) Stronger Trend PLSE
Beta / 30D Volatility
Risk Regime
0.28β · 32% Vol 1.71β · 78% Vol Lower Realized Risk DXR
Unified Institutional Score
Composite Signal
52.2 / 100 (HOLD) 40.1 / 100 (SELL) Higher Composite DXR
Trailing 12M Revenue (USD)
Operating Scale
$31,360 $1.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 26.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($8.88 Book/Sh · 14.2% ROE) -$64M ($30M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PLSE +21.21 pp
DXR: -16.87% · PLSE: +4.34%
3M Horizon PLSE +22.87 pp
DXR: -19.66% · PLSE: +3.21%
6M Horizon PLSE +148.89 pp
DXR: -17.44% · PLSE: +131.45%
1Y Horizon PLSE +261.13 pp
DXR: -33.27% · PLSE: +227.86%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DXR vs PLSE. Trailing 12-month operating profitability (DXR -5894.3% vs PLSE -5861.2%) and valuation multiples (DXR 64.5x vs PLSE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DXR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$31,360
Gross Margin100.0%
Op. Margin-5894.3%
ROE / Fwd P/E14.2% · 64.5x
PLSE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.5M
Gross Margin26.8%
Op. Margin-5861.2%
ROE / Fwd P/E-60.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PLSE CONSOLIDATION
51d in phase · OBV NEUTRAL
Current IV 73.5%
IV Percentile 10th %ile
Put/Call OI Skew 0.70x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact PLSE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DXR Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PLSE Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $3.7B market capitalization and -5861.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DXR vs PLSE Key Questions & Quantitative Answers

As of Nov 16, 2026, Pulse Biosciences, Inc (PLSE) captures the overall head-to-head institutional edge over Daxor Corporation (DXR) on higher Unified Composite conviction (40.1/100 SELL vs. 52.2/100 HOLD) after splitting the core matrix 4–6 (led by Growth & Scale, Options & Positioning), while DXR wins 3–2 across the 6-pillar growth and valuation breakdown. DXR trades at $8.36 (64.5x Forward P/E, -5894.3% operating margin) versus PLSE at $46.36 (N/M Forward P/E, -5861.2% operating margin). Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. PLSE 40.1/100 SELL), PLSE captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-5861.2% vs. -5894.3% operating margin) and revenue trajectory (+359.3% vs. +25.5% YoY). Technical & Structure Timing Caution: DXR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile PLSE trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 40.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PLSE leads the Growth & Scale pillar: DXR posts +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin), compared with PLSE at +359.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (26.8% gross margin, -5861.2% operating margin). On trailing 12-month operating scale, DXR generates $31,360 in USD-normalized revenue versus $1.5M for PLSE. In operating R&D and SG&A reinvestment, DXR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PLSE.

DXR screens cheaper on headline valuation multiples. DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PLSE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXR (14.2% ROE) versus PLSE (-60.6% ROE) capital efficiency.

In options market volatility and institutional positioning, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk). By comparison, PLSE carries 73.5% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.70x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.71β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.